Biotech Sector Leads Market Early in 2017 Despite Uncertainties…Update
Update at Close...April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with Regeneron (REGN) the big loser down 1.98%. The IBB was down 1% at $287.67 breaking the $290 technical...
Biotech in a Doldrums: Rallies Interrupted by Geopolitics, Trump Agenda and Flight to Safety
Biotech Doldrums: Nothing to Entice Buyers Trump Agenda for Tax Reform and Deregulation Stalls Geopolitical News Curbs Market Sentiment Recent geopolitical news has created a backdrop that has discouraged investors in biotech who were already risk averse from drug pricing issues. There has been...
Vertex (VRTX) Soars on Clinical Data and Boosts Biotech Stocks…Updates
Update...3/31/17 Performance %: March and YTD FBT -0.83, +15.87 FBIOX -2.43, +15.79 * Fidelity ahead of IBB in 2017 IBB -3.05,+10.5 QQQ +1.04, +11.73 XBI -2.82, +17.15 XLV -1.9, +7.86 Notable Rayno Portfolio Picks %: March and YTD ABBV +2.9, +4.08 AMGN -8.95, +12.22 BLUE +7,...
Biotech Stocks Sink with Broad Sell-Off on Political Realities…Updates
3/22 Update after close..Relief Rally Awaiting Tomorrow's Vote Large Caps-mostly green with IBB up 0.54%. Mid Caps-some strength RDUS up 3.48% SGEN up 1.74 %, ,TSRO up 4.08%. Small caps XBI up 0.98%. NASDAQ up 0.48%. ========== Biotech Stocks Sink on Trump Comments Uncertainty Mounts for GOP...
Cholesterol Stocks Clobbered: Good Clinical Results But High Expectations
Upbeat Drug Study Data from an Amgen Cholesterol Trial but Stocks are Clobbered Because of Higher Expectations LDL cholesterol is a Toxic Risk Factor Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of expectations and clobbered...